Sulfonamides and Cotrimoxazole

Classification

Sulfonamides: sulfamethoxazole, sulfadiazine, sulfasalazine(PRODRUG — gut bacteria cleave→5-ASA[local bowel action]+sulfapyridine; used in IBD/RA, NOT as systemic antibacterial). Cotrimoxazole: sulfamethoxazole+trimethoprim, 5:1 ratio(equal peak plasma conc relative to individual potency).

Mechanism

Both block SEQUENTIAL steps of SAME bacterial folate pathway: PABA→dihydropteroate→dihydrofolate→tetrahydrofolate(active cofactor, purine/thymidine synthesis→DNA replication). Humans get folate from DIET(lack synthetic enzymes) = basis of selective toxicity.

Sulfonamides: PABA structural analogue, competitive dihydropteroate synthase inhibition(1st step). Trimethoprim: dihydrofolate reductase inhibition(2nd step). Selectivity = ~50,000-fold higher affinity for BACTERIAL vs human enzyme(unlike sulfonamides’ ABSOLUTE selectivity — humans lack the target entirely).

Sequential blockade = TRUE SYNERGISM(not just additive) — each drug alone BACTERIOSTATIC, together BACTERICIDAL. + ↓resistance emergence(resistant mutant needs to overcome BOTH blocks simultaneously). Clearest direct example of the synergy principle from Antimicrobials General Considerations.

Adverse Effects

Sulfonamides: HYPERSENSITIVITY(rash → severe SJS/TEN — among MOST frequently implicated drug classes, high-yield). Crystalluria(older/less soluble agents, acidic urine→renal tubular obstruction; mitigated by newer agents+hydration). KERNICTERUS in neonates(displaces bilirubin from albumin→free bilirubin crosses immature neonatal BBB→basal ganglia deposition) → CI in neonates + 3rd trimester near delivery. Haemolysis in G6PD deficiency(oxidant stressor, can’t regenerate reduced glutathione) — one of the classic G6PD-caution oxidant drug list.

Trimethoprim: megaloblastic anaemia, leukopenia, folate-deficiency-like effects(prolonged use/marginal folate status, esp malnourished/pregnant) — DIRECT predictable consequence of DHFR inhibition despite selectivity margin. Folinic acid rescue(bypasses blocked reductase step) can be given to rescue HOST folate metabolism WITHOUT reversing antibacterial effect — same logic as methotrexate rescue in oncology.

Cotrimoxazole combined: both components’ risks + HYPERKALAEMIA(trimethoprim structurally resembles amiloride, blocks distal nephron ENaC→↓K+ secretion — DISTINCT mechanism from antifolate action, esp relevant at high-dose PCP treatment) + elevated severe hypersensitivity risk SPECIFICALLY in HIV-infected patients(well-documented, mechanism not fully settled).

Uses

Cotrimoxazole: UTIs + 1st-line treatment+prophylaxis of PCP(Pneumocystis jirovecii pneumonia) in immunocompromised/HIV(+) patients(higher dose treatment vs prophylaxis). Sulfadiazine+pyrimethamine(another DHFR inhibitor — SAME sequential-blockade synergy, applied to PROTOZOAN target) for toxoplasmosis. Sulfasalazine: gut-localized anti-inflammatory(UC, RA) — systemic antibacterial activity essentially incidental.

Clinical Relevance

Cleanest teaching example in Antimicrobials section of WHY sequential pathway blockade is deliberate, not arbitrary pairing: 2 individually bacteriostatic drugs on consecutive non-redundant steps → BACTERICIDAL together, resistance needs 2 simultaneous mutations not 1 — direct mechanistic payoff of the synergy concept from Antimicrobials General Considerations.

Classification

Sulfonamides: sulfamethoxazole, sulfadiazine, sulfasalazine (a prodrug, cleaved by gut bacteria to release 5-aminosalicylic acid for local bowel action plus sulfapyridine, used in inflammatory bowel disease/rheumatoid arthritis rather than as a systemic antibacterial)
Cotrimoxazole: a fixed-dose combination of sulfamethoxazole + trimethoprim, in a 5:1 ratio chosen to achieve roughly equal peak plasma concentrations of each drug relative to their individual potency

Mechanism of Action

Both components of cotrimoxazole block sequential steps of the same bacterial folate synthesis pathway — bacterial folate synthesis (unlike in humans, who obtain folate from the diet and lack the relevant synthetic enzymes entirely, the actual basis of selective toxicity here) proceeds through PABA → dihydropteroate → dihydrofolate → tetrahydrofolate, the active cofactor required for purine and thymidine synthesis and therefore bacterial DNA replication.

Sulfonamides: structural analogues of PABA, competitively inhibiting dihydropteroate synthase — blocking the first of the two sequential steps targeted by cotrimoxazole.

Trimethoprim: inhibits dihydrofolate reductase, the enzyme converting dihydrofolate to the active tetrahydrofolate — blocking the second sequential step. Trimethoprim’s selectivity relies on a much higher affinity for the bacterial enzyme than the human isoform (roughly 50,000-fold), the specific pharmacological basis for its safety margin despite targeting an enzyme humans also possess (unlike sulfonamides, where selectivity is absolute since humans lack the target enzyme altogether).

Sequential blockade produces true synergism, not merely additive effect — each drug individually is bacteriostatic, but blocking two consecutive steps of the same pathway together is bactericidal, and importantly, sequential blockade also substantially reduces the likelihood of resistance emerging during therapy compared with either drug alone (a resistant mutant would need to overcome both blocks simultaneously) — the same combination-therapy synergy principle already introduced under Antimicrobials — General Considerations, applied here as its clearest, most direct pharmacological example.

Adverse Effects

Sulfonamides: hypersensitivity reactions, ranging from rash to severe, potentially fatal Stevens-Johnson syndrome/toxic epidermal necrolysis — sulfonamides are among the most frequently implicated drug classes in SJS/TEN, a genuinely high-yield association. Crystalluria (older, less soluble sulfonamides could precipitate in acidic urine, causing renal tubular obstruction — largely mitigated by newer, more soluble agents and adequate hydration, but still a mechanistically important, examined point). Kernicterus risk in neonates — sulfonamides displace bilirubin from albumin binding sites, and a neonate’s immature blood-brain barrier permits free (unbound) bilirubin to cross and deposit in the basal ganglia, causing kernicterus — the specific reason sulfonamides are contraindicated in neonates and in the third trimester of pregnancy (near delivery). Haemolysis in G6PD deficiency — sulfonamides are oxidant stressors, precipitating haemolysis in glucose-6-phosphate dehydrogenase-deficient red cells (which cannot adequately regenerate reduced glutathione to buffer oxidant stress) — one of a recognized list of oxidant drugs requiring caution in this common genetic deficiency.

Trimethoprim: megaloblastic anaemia, leukopenia, and folate-deficiency-like effects with prolonged use or in patients with marginal folate status — a direct, predictable consequence of dihydrofolate reductase inhibition even at the (large) selectivity margin for the bacterial enzyme, more likely in malnourished or pregnant patients — folinic acid (already reduced, bypassing the blocked reductase step) can be co-administered to rescue host folate metabolism without reversing the antibacterial effect, the same folinic-acid-rescue logic seen with methotrexate in oncology.

Cotrimoxazole (combined): carries both components’ adverse-effect risks; hyperkalaemia (trimethoprim structurally resembles amiloride and similarly blocks epithelial Na⁺ channels in the distal nephron, reducing K⁺ secretion — a specific, examined mechanism distinct from trimethoprim’s antifolate action, particularly relevant at the high doses used for Pneumocystis jirovecii pneumonia treatment) and an elevated risk of severe hypersensitivity reactions in HIV-infected patients specifically (a well-documented, higher-than-expected incidence in this population, mechanism not fully settled).

Uses

Cotrimoxazole: urinary tract infections, and — a specific, high-yield use — first-line treatment and prophylaxis of Pneumocystis jirovecii pneumonia in immunocompromised (particularly HIV-positive) patients, at higher doses for treatment than for prophylaxis. Sulfadiazine (often combined with pyrimethamine, another dihydrofolate reductase inhibitor, applying the identical sequential-blockade synergy principle to a protozoan target instead) for toxoplasmosis. Sulfasalazine, as noted, functions differently — its systemic antibacterial sulfonamide activity is essentially incidental to its actual gut-localized anti-inflammatory use in ulcerative colitis and rheumatoid arthritis.

Clinical Relevance

Cotrimoxazole is the cleanest teaching example in the entire Antimicrobials section of why sequential pathway blockade is combined deliberately rather than being an arbitrary pairing — two individually bacteriostatic drugs targeting consecutive, non-redundant steps of one pathway becoming bactericidal together, with resistance requiring two simultaneous mutations rather than one, is the direct, mechanistic payoff of the synergy concept introduced generally in Antimicrobials — General Considerations.

Bacterial folate synthesis pathway (PABA → dihydropteroate → dihydrofolate → tetrahydrofolate) with sulfonamide and trimethoprim’s sequential blocking points marked.
Kernicterus mechanism: sulfonamide displacing bilirubin from albumin, crossing an immature neonatal blood-brain barrier.